Serostim Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to availability of recombinant somatropin formulations, improved management of HIV-associated wasting, expansion of antiretroviral therapy access, increased clinical recognition of cachexia, development of specialty endocrinology treatments.

The growth in the forecast period can be attributed to increasing focus on quality-of-life improving therapies, rising adoption of adjunctive HIV treatments, expansion of home-based care models, growing demand for metabolic support therapies, advancements in long-acting hormone formulations. Major trends in the forecast period include increasing use of recombinant growth hormone therapies, rising focus on cachexia management, growing emphasis on body composition improvement treatments, expansion of long-term hormone therapy programs, enhanced monitoring of treatment outcomes.

The rising incidence of HIV/AIDS is expected to drive the growth of the serostim market going forward. HIV/AIDS is a viral infection that weakens the immune system and can progress to acquired immunodeficiency syndrome (AIDS) if left untreated. The increase in HIV/AIDS cases is linked to factors such as unprotected sexual activity, limited access to healthcare, low awareness, and social stigma, all of which facilitate the spread of the virus. Serostim supports HIV/AIDS patients by promoting weight gain, increasing lean body mass, and enhancing physical strength, thereby counteracting HIV-associated wasting and improving overall quality of life. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, England recorded 6,008 new HIV diagnoses in 2023, a 51% increase compared to 3,975 diagnoses in 2022. Therefore, the rising incidence of HIV/AIDS is driving the growth of the serostim market.

The growing incidence of chronic diseases is expected to propel the growth of the serostim market going forward. Chronic diseases are long-term medical conditions that persist for a year or more and often require ongoing management, including diabetes, cardiovascular disease, and asthma. The increase in chronic diseases is largely driven by sedentary lifestyles, which contribute to weight gain, metabolic imbalances, and reduced cardiovascular health. Serostim supports patients with chronic diseases by improving muscle mass, energy levels, and metabolic stability, which enhances physical function and helps individuals manage long-term health complications more effectively. For instance, in July 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australian government health statistics agency, chronic conditions accounted for 78% of the total fatal burden, reflecting an increase compared to previous years. Therefore, the growing incidence of chronic diseases is driving the growth of the serostim market.

The rising prevalence of target diseases is expected to drive the growth of the serostim market going forward. Target diseases are specific health conditions or illnesses that are the primary focus of treatment, intervention, or research due to their prevalence or severity. The increasing prevalence of these diseases is influenced by factors such as aging populations, unhealthy lifestyle habits, environmental factors, and improved detection methods. Serostim helps prevent or reverse muscle wasting and loss of lean body mass by stimulating growth hormone receptors to enhance protein synthesis, thereby rebuilding muscle and tissue. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Therefore, the rising prevalence of target diseases is driving the growth of the serostim market.

Major companies operating in the serostim market are EMD Serono Inc.

North America was the largest region in the serostim market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the serostim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the serostim market by increasing costs of imported bioreactors, fermentation inputs, purification systems, and injectable drug delivery components used in recombinant hormone production. North America and Europe are most affected due to reliance on specialized biologics manufacturing equipment, while other regions face increased distribution costs. These tariffs contribute to higher therapy pricing and supply chain complexity. However, they are also promoting domestic biomanufacturing expansion, localized hormone production, and investments in regional biologics supply chains to ensure long-term availability.

The serostim market research report is one of a series of new reports that provides serostim market statistics, including serostim industry global market size, regional shares, competitors with a serostim market share, detailed serostim market segments, market trends and opportunities, and any further data you may need to thrive in the serostim industry. This serostim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Serostim is a recombinant human growth hormone (somatropin) formulated to treat HIV-associated wasting or cachexia. It is used to enhance body weight, lean body mass, and physical endurance in patients experiencing substantial weight loss due to HIV.

The primary indication for Serostim is HIV-associated wasting syndrome and cachexia. HIV-associated wasting syndrome is a condition in which individuals with HIV experience significant weight loss, muscle wasting, and a decline in overall health as a result of the virus's effects on the body. The medication is distributed through direct sales, pharmacies, and wholesalers, and is used in settings such as hospitals, clinics, ambulatory care, and home care.

The serostim consists of sales of lyophilized powder for injection, pre-filled syringes, and cartridge formulations for injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.